CompletedPhase 1NCT02026271

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma

Studying Glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Alaunos Therapeutics
Principal Investigator
Jaymes Holland, BC-HIS
Alaunos Therapeutics
Intervention
Ad-RTS-hIL-12(biological)
Enrollment
40 enrolled
Eligibility
18-75 years · All sexes
Timeline
20152019

Study locations (6)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02026271 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma

← Back to all trials